Each week we highlight five things affecting the life sciences industry. Here’s the latest.
FDA pushes real-time clinical trials forward
- The U.S. Food and Drug Administration announced new initiatives to enable real-time clinical trials using continuous data collection and advanced digital tools to speed up evidence generation.
- According to FDA, these efforts aim to improve trial efficiency, enhance patient monitoring, and support faster, more adaptive regulatory decision-making.
Federal Trade Commission intensifies health care oversight
- The Federal Trade Commission announced the formation of a Healthcare Task Force aimed to strengthen coordination across the FTC with regards to health care related issues.
- According to JD Supra, authorities are signaling stricter action against consolidation and deceptive practices through this coordinated effort.
Data breach hits leading medtech
- An unauthorized third party accessed a leading medtech’s corporate IT systems, prompting an ongoing investigation and containment effort.
- Reports MedTech Dive, the breach affected corporate IT infrastructure rather than the devices themselves, with steps underway to strengthen security and notify impacted parties.
J&J notes accelerated drug discovery timeline with AI
- Advances in artificial intelligence are significantly reducing the time needed to identify promising drug candidates, potentially transforming early-stage development workflows, reports Johnson and Johnson’s chief information officer.
- According to Reuters, new internal estimates at J&J suggest AI could cut the timeline for generating drug development leads by up to 50%.
Faster Medicare access for breakthrough devices
- Regulators have introduced a new pathway designed to accelerate Medicare coverage decisions for innovative medical devices, aiming to improve patient access.
- Per MedTech Dive, the initiative aligns review processes to shorten timelines and streamline coordination between agencies overseeing approval and reimbursement.
For more insights in life sciences, check out RSM’s industry outlook.
